Annovis Bio (ANVS) Projected to Post Quarterly Earnings on Tuesday

Posted by on May 12th, 2026

Annovis Bio (NYSE:ANVS – Get Free Report) is anticipated to issue its Q1 2026 results before the market opens on Tuesday, May 19th. Analysts expect the company to announce earnings of ($0.3950) per share for the quarter. Parties may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Tuesday, May 19, 2026 at 12:00 AM ET.

Annovis Bio (NYSE:ANVS – Get Free Report) last released its quarterly earnings data on Friday, March 13th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.08).

Annovis Bio Price Performance

NYSE:ANVS opened at $2.40 on Tuesday. Annovis Bio has a 1 year low of $1.48 and a 1 year high of $5.50. The stock’s 50 day simple moving average is $2.22 and its two-hundred day simple moving average is $2.82. The company has a market cap of $82.98 million, a price-to-earnings ratio of -1.71 and a beta of 1.26.

Insider Buying and Selling

In other Annovis Bio news, Director Michael B. Hoffman acquired 713,800 shares of the business’s stock in a transaction on Thursday, April 2nd. The shares were bought at an average price of $2.10 per share, with a total value of $1,498,980.00. Following the transaction, the director directly owned 3,288,539 shares of the company’s stock, valued at $6,905,931.90. The trade was a 27.72% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. 20.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Annovis Bio

Several hedge funds have recently bought and sold shares of ANVS. Wells Fargo & Company MN grew its position in shares of Annovis Bio by 46.8% during the 4th quarter. Wells Fargo & Company MN now owns 14,307 shares of the company’s stock worth $50,000 after buying an additional 4,561 shares in the last quarter. Bridgeway Capital Management LLC grew its position in shares of Annovis Bio by 25.8% during the 4th quarter. Bridgeway Capital Management LLC now owns 24,400 shares of the company’s stock worth $84,000 after buying an additional 5,000 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Annovis Bio by 69.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 14,900 shares of the company’s stock worth $32,000 after buying an additional 6,100 shares in the last quarter. RKL Wealth Management LLC bought a new position in shares of Annovis Bio during the 4th quarter worth $35,000. Finally, Wealthspire Advisors LLC grew its position in shares of Annovis Bio by 100.0% during the 4th quarter. Wealthspire Advisors LLC now owns 20,000 shares of the company’s stock worth $69,000 after buying an additional 10,000 shares in the last quarter. Institutional investors own 15.83% of the company’s stock.

Analyst Upgrades and Downgrades

ANVS has been the topic of a number of recent research reports. Weiss Ratings downgraded Annovis Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 29th. Canaccord Genuity Group reissued a “buy” rating and set a $17.00 target price on shares of Annovis Bio in a research report on Tuesday, April 14th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $13.50.

Check Out Our Latest Stock Analysis on Annovis Bio

About Annovis Bio

(Get Free Report)

Annovis Bio, Inc (NYSE: ANVS) is a clinical-stage biotechnology company headquartered in Tampa, Florida, focused on the discovery and development of small molecule therapeutics for neurodegenerative and neuroinflammatory disorders. Leveraging a proprietary platform that targets protein trafficking and translational dysregulation, Annovis aims to restore cellular homeostasis by modulating the production and clearance of disease-related proteins. The company’s pipeline is designed to address critical pathways implicated in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and other central nervous system conditions.

The company’s lead asset, ANVS401 (Posiphen®), is an oral small molecule that has been evaluated in Phase 1 and Phase 2 clinical trials to reduce levels of amyloid precursor protein and its toxic fragments in Alzheimer’s patients.

Featured Articles

Earnings History for Annovis Bio (NYSE:ANVS)

Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.